News Image

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Provided By GlobeNewswire

Last update: Oct 12, 2024

-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-

Read more at globenewswire.com

BENITEC BIOPHARMA INC

NASDAQ:BNTC (7/24/2025, 1:14:40 PM)

12.12

+0.27 (+2.28%)



Find more stocks in the Stock Screener

Follow ChartMill for more